Analyst Price Targets — ILMN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 12:01 pm | — | Piper Sandler | $170.00 | $119.72 | TheFly | Illumina price target lowered to $170 from $195 at Piper Sandler |
| February 6, 2026 2:46 pm | Catherine Ramsey Schulte | Robert W. Baird | $137.00 | $120.22 | TheFly | Illumina price target raised to $137 from $132 at Baird |
| February 6, 2026 1:25 pm | — | UBS | $135.00 | $121.27 | TheFly | Illumina price target raised to $135 from $120 at UBS |
| February 6, 2026 1:20 pm | — | Evercore ISI | $150.00 | $121.13 | TheFly | Illumina price target lowered to $150 from $155 at Evercore ISI |
| January 26, 2026 2:35 pm | Subbu Nambi | Guggenheim | $170.00 | $150.38 | TheFly | Illumina price target raised to $170 from $144 at Guggenheim |
| January 26, 2026 11:21 am | — | Canaccord Genuity | $150.00 | $150.28 | TheFly | Illumina price target raised to $150 from $130 at Canaccord |
| January 20, 2026 12:28 pm | Daniel Arias | Stifel Nicolaus | $155.00 | $141.65 | TheFly | Illumina price target raised to $155 from $135 at Stifel |
| January 5, 2026 2:50 pm | Vijay Kumar | Evercore ISI | $155.00 | $138.50 | TheFly | Illumina price target raised to $155 from $142 at Evercore ISI |
| January 5, 2026 2:27 pm | — | Guggenheim | $144.00 | $138.11 | TheFly | Illumina price target raised to $144 from $114 at Guggenheim |
| December 15, 2025 10:55 am | — | Barclays | $110.00 | $134.85 | TheFly | Illumina price target raised to $110 from $100 at Barclays |
Latest News for ILMN
Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalization, and machine learning features boost analytical capabilities across applications SAN DIEGO, April 16, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software…
Illumina, Inc. (NASDAQ: ILMN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the
Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.